PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as 'the Company' or 'PHAXIAM,' a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its shares from Euronext, as previously announced. PHAXIAM reiterates that no reimbursement to shareholders can be made.
Despite the efforts undertaken by the Company and its management to extend its financing horizon and maintain its operations, extremely challenging market conditions—particularly for small-cap listed biotech companies—did not allow for the implementation of a viable refinancing solution, leading the Company to file for receivership in early March 2025.
Since 2017, PHAXIAM has provided more than 140 patients with phage-based treatments produced under pharmaceutical-grade standards, within a compassionate use framework. The Company sincerely hopes that these patients will continue to receive appropriate medical care and support despite the cessation of its activities.
PHAXIAM would like to express its deep gratitude to all its stakeholders – including employees, partners, healthcare professionals, and shareholders – for their dedication and support throughout its journey.
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Share Buyback Transaction Details July 10 – July 16, 2025
PRESS RELEASE Share Buyback Transaction Details July 10 – July 16, 2025 Alphen aan den Rijn – July 17, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 196,897 of its own ordinary shares in the period from July 10, 2025, up to and including July 16, 2025, for €27.4 million and at an average share price of €139.16. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 3,885,856 590.6 151.99 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.07.17 Share Buyback Transactions Jul 10 - 16 2025
Business Wire
6 hours ago
- Business Wire
GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder
PARIS--(BUSINESS WIRE)--Regulatory News: This additional financing provides valuable flexibility as we execute our operational roadmap through October 2025. NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the " Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced a financing through a capital increase reserved to an existing shareholder by the issuance of new shares with warrants attached, for a total gross amount of EUR 499,999.92 (excluding the future net proceeds related to the exercise of the warrants) (the " Reserved Offering"). The subscription price for one ABSA is EUR 0.17 (the " Offering Price"). This follows the approximately EUR 4 million financing announced on July 1, 2025 (the ' Early July Financing '). The Offering Price of the ABSA and the terms and conditions of the warrants, including their exercise price, are identical to those included in the Early July Financing. " We are delighted to receive this additional support from an existing shareholder, as we continue to pursue GenSight's strategic direction and LUMEVOQ's potential, ' commented Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. " This supplementary funding, combined with our recent EUR 4 million financing, strengthens our position as we advance toward the anticipated opening of the French AAC program in Q4 2025 and prepare for our global Phase III RECOVER study." The New Shares (as defined below) represent less than 30% of the total number of the Company's ordinary shares already admitted to trading on Euronext Paris. The admission to trading of the New Shares on Euronext Paris is therefore exempted from the obligation to prepare a prospectus. Use of Proceeds The proceeds of the Reserved Offering will supplement the funds raised in the Early July Financing. Together, they are intended to be used principally to finance the continued development of LUMEVOQ ®, the Company's most advanced drug candidate, currently in Phase III. In particular, the funds raised will help ensure the Company's operational continuity, support the finalization of manufacturing transfer activities and secure the preparations for the anticipated opening of compassionate use access in France as well as the initiation of the Phase III study RECOVER. The balance will be used to meet certain financial obligations of the Company. This will extend the Company's cash runway from mid-July 2025 before the Early July Financing to early-October 2025 initially and now to mid-October 2025. " This additional financing provides valuable flexibility as we execute our operational roadmap through October 2025, ' noted Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. " We believe the support of UPMC Enterprises reflects the attractiveness of our investment proposition. We remain focused on achieving key regulatory milestones that will establish a sustainable revenue pathway, beginning with the AAC program." Terms and Conditions of the Reserved Offering The Reserved Offering, for a total of EUR 499,999.92 (share issue premium included), was carried out through the issuance of 2,941,176 ABSA (as defined below) via a capital increase without shareholders' preferential subscription rights reserved to a category of persons satisfying determined characteristics, pursuant to Article L. 225-138 of the French Commercial Code, through the issuance of new shares of a per value of EUR 0.025 (the " New Shares"), to which are attached 1 warrant for 1 new share (the " Warrants", together with the New Shares, the " ABSA" and with the new shares of the Company resulting from the exercise of the Warrants, the " Warrant Shares"). The launch of the Reserved Offering was decided on July 16, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to her by the Company's board of directors (the ' Board of Directors ') on June 19 and June 30, 2025. The Board of Directors acted pursuant to the delegation of competence granted to it under the 24 th resolution of the Company's shareholders on May 13, 2025 (the ' General Meeting '). The EUR 0.17 issue price on one ABSA represents a facial premium of EUR 0.0492 to the closing price of the GenSight shares on Euronext Paris on the day of the determination of the issue price, i.e., EUR 0.1208 on July 16, 2025. The exercise price of the Warrants is EUR 0.21. The Warrants will be exercisable at any time from their issue date until July 21, 2030. The exercise of a Warrant will give the right to subscribe to one (1) Warrant Share (the " Exercise Ratio"), it being specified that this Exercise Ratio may be adjusted following any transactions carried out by the Company on its share capital or reserves, as from the issuance date of the Warrants, in order to maintain the rights of the Warrants' holders. Impact of the Reserved Offering on the Company's Shareholding Following the issuance of the New Shares, the Company's total share capital will be EUR 3,891,473.45 (composed of 155,658,938 ordinary shares). If all the Warrants are exercised, and thus all the Warrant Shares issued, the Company's total share capital will be EUR 3,965,002.85 (composed of 158,600,114 ordinary shares). Please see sections 19.1.3 and 19.1.4 of the Company's 2024 Universal Registration Document and the press release dated July 1, 2025 relating to the Early July Financing for a description of the securities issued by GenSight and giving access to its capital. For illustration purposes, the impact of the issuance of the New Shares and the Warrant Shares on the ownership of a shareholder holding 1% of the Company's share capital prior to the Reserved Offering and not subscribing to it, is as follows: Impact of the Reserved Offering on Shareholders' Equity For illustration purposes, the impact of the issuance of the New Shares and the Warrant Shares on the Company's equity per share (calculation made on the basis of the Company's shareholders' equity as reflected in the consolidated financial statements as of December 31, 2024, adjusted for the capital increase of March 7, 2025, the conversion of 631,560 Heights convertible bonds into 1,930,195 new shares on April 1, 2025, in accordance with the amendment dated June 27, 2024 to the convertible bond agreement, and the capital increase of July 1, 2025) is as follows: Evolution of the Shareholding Structure following the Reserved Offering To the Company's knowledge, immediately prior to completion of the Reserved Offering, the breakdown of the Company's share capital was as follows: Shareholders Shareholding (non-diluted) Shareholding (diluted) 3 Number of shares and voting rights % of share capital and voting rights Number of shares and voting rights % of share capital and voting rights 5% Shareholders Sofinnova 4 35,795,627 23.4 % 53,106,527 20.4 % Invus 5 21,512,773 14.1 % 30,535,967 11.7 % UPMC Enterprises 6 10,158,364 6.7 % 12,487,477 4.8 % Heights 7 14,900,613 9.8 % 70,347,580 27.1 % BPI 3,877,591 2.5 % 5,355,501 2.1 % Directors and Officers 517,002 0.3 % 2,388,335 0.9 % Employees 352,500 0.2 % 392,500 0.2 % Other shareholders (total) 65,603,292 43.0 % 85,398,945 32.8 % Total 152,717,762 100.00 % 260,012,832 100.00 % Expand To the Company's knowledge, immediately after the completion of the Reserved Offering and the issuance of the New Shares, the breakdown of the Company's share capital will be as follows: Shareholders Shareholding (non-diluted) Shareholding (diluted) Number of shares and voting rights % of share capital and voting rights Number of shares and voting rights % of share capital and voting rights 5% Shareholders Sofinnova 35,795,627 23.0 % 53,106,527 20.0 % Invus 21,512,773 13.8 % 30,535,967 11.5 % UPMC Enterprises 13,099,540 8.4 % 18,369,829 6.9 % Heights 14,900,613 9.6 % 70,347,580 26.5 % BPI 3,877,591 2.5 % 5,355,501 2.0 % Directors and Officers 517,002 0.3 % 2,388,335 0.9 % Employees 352,500 0.2 % 392,500 0.1 % Other shareholders (total) 65,603,292 42.1 % 85,398,945 32.1 % Total 155,658,938 100.0 % 265,895,184 100.0 % Expand To the Company's knowledge, after the completion of the Reserved Offering and the issuance of the New Shares and all Warrant Shares upon exercise of all Warrants, the breakdown of the Company's share capital will be as follows: Shareholders Shareholding (non-diluted) Shareholding (diluted) Number of shares and voting rights % of share capital and voting rights Number of shares and voting rights % of share capital and voting rights 5% Shareholders Sofinnova 35,795,627 22.6 % 53,106,527 20.0 % Invus 21,512,773 13.6 % 30,535,967 11.5 % UPMC Enterprises 16,040,716 10.1 % 18,369,829 6.9 % Heights 14,900,613 9.4 % 70,347,580 26.5 % BPI 3,877,591 2.4 % 5,355,501 2.0 % Directors and Officers 517,002 0.3 % 2,388,335 0.9 % Employees 352,500 0.2 % 392,500 0.1 % Other shareholders (total) 65,603,292 41.4 % 85,398,945 32.1 % Total 158,600,114 100.0 % 265,895,184 100.0 % Expand Admission to Trading of the New Shares and the Warrants Settlement-delivery of the Reserved Offering and the admission of the New Shares to trading on the regulated market of Euronext Paris are expected on July 21, 2025. The New Shares and the Warrant Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Reserved Offering. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0013183985 / SIGHT. The Warrants are expected to be admitted to trading on the Euronext Growth market in Paris (" Euronext Growth Paris") on July 21, 2025 on the same warrant listing line as the Company's existing warrants under the same ISIN code FR0014010IB4/SIGBS. The Warrant Shares will be admitted to trading on Euronext Paris as they are issued following the exercise of the corresponding warrants. Lock-up Commitments The benefit of the lock-up commitments agreed by the Company (45 days) and directors and officers of the Company (60 days) has been extended to UPMC Enterprises. Indicative Timetable July 16, 2025 Decision of the Chief Executive Officer setting the terms and conditions of the Reserved Offering. July 17, 2025 Publication of this press release. July 18 or 21, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. July 21, 2025 Settlement-delivery of the ABSAs - Detachment of the Warrants - Start of trading of the New Shares on Euronext Paris. Admission of the Warrants on Euronext Growth Paris Expand Risk Factors The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2024 Universal Registration Document, as updated in the Information Document made available in connection with the Early July Financing, which are available free of charge on the Company's website ( . In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Reserved Offering will see their shareholding in the share capital of GenSight diluted, and this shareholding may also be further diluted in the event of the exercise of the Warrants, as well as in the event of new securities transactions. The volatility and liquidity of GenSight shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Reserved Offering. The sale of Company shares may occur on the secondary market, after the Reserved Offering, and have a negative impact on the Company share price. About GenSight Biologics S.A. GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Disclaimer Not for release, directly or indirectly, in or into the United States of America, Canada, Australia, Japan or South Africa. This press release and the information contained herein do not contain or constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for securities in the United States of America or in any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or any other jurisdiction of the United States. GenSight does not intend to make a public offering of the securities in the United States of America. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. Forward-Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Reserved Offering; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' and 'future' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Reserved Offering and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the Autorité des marchés financiers from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. 1 The number of shares contained in the table includes 107,295,070 shares that may be issued by the Company further to the exercise of the remaining share warrants, founders share warrants, free shares and stock options outstanding, including the share warrants issued as part of the Early July Financing. 2 Idem. 3 Idem. 4 Sofinnova Partners: French management company located at 7-11 boulevard Haussmann, 75009 Paris, France, which manages Sofinnova Crossover I SLP. 5 Invus: a Bermudian company located at Clarendon House, 2 Church Street, Hamilton HM 11 Bermuda. Pursuant to the provisions of Article L. 233-9 I, 4° bis of the French Commercial Code, Invus has stated that they hold 6,360,058 shares of GENSIGHT BIOLOGICS S.A. as a result of holding "contracts for differences" ("CFDs") maturing on January 3, 2034, covering an equivalent number of GENSIGHT BIOLOGICS S.A. shares, to be settled in cash. 6 UPMC Enterprises: a non-profit organization located at 6425 Penn Avenue, Suite 200, Pittsburgh, Pennsylvania, United States of America. 7 Heights Capital: a Cayman Islands exempted company located at PO Box 309GT, Ugland House South Church Street, George Town Grand Cayman, Cayman Islands.
Yahoo
6 hours ago
- Yahoo
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 million Tiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa will assume full responsibility for the preparation and filing costs of the U.S. NDA for NCX 470, and all future development and commercial costs Provides flexibility for Nicox to explore future growth options July 17, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing. The agreement, worth up to €191.5 million, grants Kowa exclusive rights to develop and commercialize NCX 470, Nicox's nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension in the U.S. and all other territories of the world excluding Japan, China, Korea and Southeast Asia. Kowa already has a license to NCX 470 for Japan, where it is preparing to enter a Phase 3 clinical trial. NCX 470 is also licensed to Ocumension Therapeutics for China, Korea and Southeast the terms of the agreement, Nicox will receive an upfront payment of €7.5 million on signing. Additional near-term milestones payments are due on positive topline results from the Denali clinical trial, expected mid-August to mid-September 2025, and on submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which is currently expected in H2 2026. The total potential development and sales milestones payments will be either €127 million or €191.5 million, depending on the outcome of the Denali clinical trial, plus royalties up to 20% in the U.S. 'This new agreement with our existing partner, Kowa, is a major endorsement of NCX 470's potential in glaucoma and marks a major step forward in strengthening Nicox's financial position. With NCX 470 now globally licensed, we are focused on delivering the Denali Phase 3 results, which we anticipate releasing mid-August to mid-September.' said Gavin Spencer, Chief Executive Officer of Nicox. 'The revenue stream we expect from NCX 470 gives us the flexibility to pursue future growth opportunities, leveraging our expert U.S. ophthalmology development team.''Expanding our collaboration with Kowa, who now becomes our key commercial partner for NCX 470 in the U.S and other major territories, is based on a very successful history of working together. We believe that Kowa has recognised the significant market potential of NCX 470, which we expect to be confirmed with the upcoming results from the Denali Phase 3 trial.' said Emmet Purtill, VP Business Development of Nicox. 'We look forward to continuing to work with Kowa as well as our partner for the Chinese market, Ocumension, to bring NCX 470 to glaucoma patients worldwide.' Details of the AgreementUnder the terms of the exclusive licensing agreement, Kowa is granted rights to develop and commercialize NCX 470 worldwide, excluding the territories already licensed to Ocumension (China, Korea and Southeast Asia) and to Kowa itself (Japan). The collaboration will be managed by a Joint Steering Committee. Key terms include:Milestone PaymentsNicox will receive an upfront payment of €7.5 million upon signing the agreement. Additional near-term milestones payments are due on positive topline results from the Denali Phase 3 clinical trial, expected mid-August to mid-September 2025 and upon submission of an NDA to the FDA, which is currently expected in H2 2026. The total potential development and sales milestones payments will be either €127 million or €191.5 million, depending on the outcome of the Denali clinical trial. Royalty PaymentsKowa will pay Nicox tiered royalties in the U.S. which could reach 20% of net sales. Depending on the results of the Denali clinical trial, royalties due in the U.S. will initially be 8% or 10%. Outside of the U.S., Nicox will receive tiered royalties ranging from single-digit to double-digit percentages. Nicox ObligationsNicox is responsible, at its cost, for generating the remaining development data necessary for the NDA submission to the FDA (principally pharmacokinetic studies) and will support Kowa in preparation of the ObligationsOther than the activities for which Nicox is responsible, Kowa is responsible, at its cost, for all development, regulatory and commercialization activities for NCX 470 in the licensed Runway and Debt RepaymentAs disclosed in the amended bond agreement announced on 14 October 2024, 70% of the upfront payment from Kowa will be used to partially reimburse Nicox's debt, reducing the total debt to €9.6 million. Based on the current cash position (estimated1 at €5.9 million as of 30 June 2025) expected revenue and anticipated milestone payments, Nicox forecasts that it has over 12 months of cash at the date of signature of this agreement. Glaucoma Pharmaceutical MarketThe glaucoma pharmaceutical market is estimated at over $7 billion2, with the U.S. market accounting for around 40%, growing globally at around 3% to 5% CAGR and the number of patients globally is estimated to be around 80 million3. About NCX 470NCX 470, Nicox's lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development in the U.S., China and Japan (clinical trial authorisation granted for Japan) for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last patient in Denali has completed their final visit, and the results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. All remaining NDA-enabling pharmacokinetic and non-clinical studies necessary to support the U.S. NDA filing are on track. A separate Phase 3 program is underway to support Japanese approval, with the first patient expected to be enrolled in H2 2025. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia, and to Kowa in the rest of the world. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Non-audited figure 2 Antiglaucoma Drug Market Size, Trends, Growth Report 2034; Glaucoma Therapeutics Market Report by Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others); Glaucoma Therapeutics Market Size, Growth, Analysis - 20313 World Glaucoma Association website: World Glaucoma Association » What is glaucoma? Attachment EN_NCX470KowaGlobalLicenseJuly2025_PR_FINALError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
